Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - Seite 3

Percentage of patients with Grade 4 Treatment-Emergent Adverse Events (TEAEs)	Grade 4 TEAEs
Control Arm (SoC alone)	0% (0 of 7)
Onvansertib 20 mg + SoC	25% (2 of 8)
Onvansertib 30 mg + SoC	0% (0 of 7)
Onvansertib (all doses) + SoC	13% (2 of 15)

• The combination of onvansertib with SoC FOLFIRI/bev was shown to be well-tolerated and no major / unexpected toxicities were seen
• Two Grade 4 TEAEs of neutropenia were seen in patients receiving 20 mg Onvansertib + SOC
  • Both patients recovered within 7 and 10 days after withholding the study treatment and no dose reductions in subsequent treatment cycles were needed. Both patients are still on trial
    

Key Baseline Characteristics

• The patients' median age was 53 years (range 35-81), and 54% were male
• 68% patients had previously received bev in their first-line treatment
• 12 of 21 (57%) evaluable patients remain on trial at the data cutoff date
  

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at www.cardiffoncology.com. A webcast replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.